According to GuruFocus' All-in-One Screener, the following are some of the stocks that have outperformed the Standard & Poor's 500 Index over the last 12 months and were bought by gurus during the last quarter.
Albemarle Corp. (ALB, Financial) with a market cap of $11.61 billion has outperformed the S&P 500 Index by 10.4% in the last year.
Albemarle manufactures engineered specialty chemicals for various end markets, including petroleum refining, consumer electronics, construction, automotive, lubricants and pharmaceuticals.
Its shares are trading with a price-book (P/B) ratio of 3.19. According to the discount cash flow (DCF) calculator, the company is overpriced by 238% at $104.85 per share. The price is 40.06% above its 52-week low and 10.11% below its 52-week high.
The company has a profitability and growth rating of 5 out of 10. Its return on equity (ROE) of -13.39% and return on assets (ROA) of 5.34% are outperforming 55% of other companies in in the Global Specialty Chemicals industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.73 is below the industry median of 0.74.
The company’s largest shareholder among the gurus is Spiros Segalas (Trades, Portfolio) with 1.8% of outstanding shares, followed by Steve Mandel (Trades, Portfolio) with 1.78%, First Eagle Investment (Trades, Portfolio) with 0.5%, Chuck Royce (Trades, Portfolio) with 0.37%, Joel Greenblatt (Trades, Portfolio) with 0.18%, Pioneer Investments (Trades, Portfolio) with 0.06%, Steven Cohen (Trades, Portfolio) with 0.03% and Mario Gabelli (Trades, Portfolio) with 0.03%.
Align Technology Inc.Ă‚ (ALGN, Financial) with a market cap of $12.33 billion has outperformed the S&P 500 Index by 72.3% over the last 12 months.
The company designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and other devices used in dentistry and orthodontics.
Its shares are trading with a P/B ratio of 11.80. According to the DCF calculator, the stock is overpriced by 433% at $153.5 per share. The price is 99.17% above its 52-week low and 0.87% below its 52-week high.
The company has a profitability and growth rating of 8 out of 10. Its ROE of -22.70% and ROA of 16.38% are outperforming 92% of other companies in the Global Medical Devices industry. Financial strength has a rating of 9 out of 10 with no debt.
Mandel is the largest shareholder of the company among the gurus with 3.08% of outstanding shares, followed by Jim Simons (Trades, Portfolio) with 1.78%, Columbia Wanger (Trades, Portfolio) with 1.43%, RS Investment Management (Trades, Portfolio) with 0.75%, Pioneer Investments with 0.3%, Ken Fisher (Trades, Portfolio) with 0.12%, John Hussman (Trades, Portfolio) with 0.06% and Ruane Cunniff (Trades, Portfolio) with 0.06%.
Alaska Air Group Inc.Ă‚ (ALK, Financial) with a market cap of $11.33 billion has outperformed the S&P 500 Index by 41.6% in the last year.
The company provides passenger air, freight and mail services.
Its shares are trading with a P/B ratio of 3.76. According to the DCF calculator, the stock is overpriced by 46% at $91.63 per share. The price is 68.10% above its 52-week low and 9.66% below its 52-week high.
The company has a profitability and growth rating of 8 out of 10. Its ROE of -26.24% and ROA of 8.51% are outperforming 73% of other companies in the Global Airlines industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.60 is above the industry median of 0.51.
The company’s largest shareholder among the gurus is PRIMECAP Management (Trades, Portfolio) with 4.91% of outstanding shares, followed by Simons with 1.69%, Diamond Hill Capital (Trades, Portfolio) with 0.22%, Greenblatt with 0.12%, Pioneer Investments with 0.1%, Cohen with 0.09% and John Buckingham (Trades, Portfolio) with 0.01%.
Alkermes PLCĂ‚ (ALKS, Financial) with a market cap of $8.96 billion has outperformed the S&P 500 Index by 18.4% over the last 12 months.
The biopharmaceutical company develops products to address patients' unmet medical needs.
Its shares are trading with a P/B ratio of 7.36. The price is 47.47% above its 52-week low and 7.78% below its 52-week high.
The company has a profitability and growth rating of 5 out of 10. Its ROE of -16.27% and ROA of -11.43% are underperforming 65% of other companies in the Global Biotechnology industry. Financial strength has a rating of 6 out of 10. The cash-debt ratio of 1.68 is below the industry median of 37.83.
The Vanguard Health Care Fund (Trades, Portfolio) is the largest shareholder of the company among the gurus with 5.68% of outstanding shares, followed by PRIMECAP Management (Trades, Portfolio) with 5.13%, Cohen with 0.16%, Simons with 0.08%, Fisher with 0.07% and Greenblatt with 0.03%.
Allstate Corp. (ALL, Financial) with a market cap of $32.11 billion has outperformed the S&P 500 Index by 16.6% in the last year.
The insurance company provides property liability insurance, life insurance and retirement and investment products in the U.S. and Canada.
Its shares are trading with a P/B ratio of 1.66. According to the DCF calculator, the stock is overpriced by 39% at $88.08 per share. The price is 34.95% above its 52-week low and 2.93% below its 52-week high.
The company has a profitability and growth rating of 6 out of 10. Its ROE of -10.67% and ROA of 2.15% are outperforming 50% of other companies in the Global Insurance - Property and Casualty industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.07 is below the industry median of 2.41.
The company’s largest shareholder among the gurus is David Tepper (Trades, Portfolio) with 0.51% of outstanding shares, followed by Richard Pzena (Trades, Portfolio) with 0.4%, Simons with 0.34%, Hotchkis & Wiley with 0.18%, Robert Bruce (Trades, Portfolio) with 0.09%, Pioneer Investments with 0.02%, Buckingham with 0.01% and David Dreman (Trades, Portfolio) with 0.01%.
Ally Financial Inc.Ă‚ (ALLY, Financial) with a market cap of $9.43 billion has outperformed the S&P 500 Index by 8.7% over the last 12 months.
The company offers diversified financial products to consumers, businesses, automotive dealers and corporate clients.
Its shares are trading with a P/B ratio of 0.71. According to the DCF calculator, the stock is undervalued with a margin of safety of 14% at $20.54 per share. The price is 38.41% above its 52-week low and 13.04% below its 52-week high.
The company has a profitability and growth rating of 5 out of 10. Its ROE of 7.50% and ROA of 0.65% are underperforming 59% of other companies in the Global Specialty Finance industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.07 is below the industry median of 2.10.
Bill Nygren (Trades, Portfolio) is the largest shareholder of the company among the gurus with 3.8% of outstanding shares, followed by First Pacific Advisors (Trades, Portfolio) with 2.36%, Howard Marks (Trades, Portfolio) with 2.26%, Steven Romick (Trades, Portfolio) with 2.17%, Richard Perry (Trades, Portfolio) with 0.9%, Simons with 0.67% and Richard Snow (Trades, Portfolio) with 0.6%.
Alnylam Pharmaceuticals Inc. (ALNY, Financial) with a market cap of $7.34 billion has outperformed the S&P 500 Index by 34.3% in the last year.
The biopharmaceutical company develops novel therapeutics based on RNA interference.
Its shares are trading with a P/B ratio of 8.82. The price is 171.54% above its 52-week low and 1.94% below its 52-week high.
The company has a profitability and growth rating of 1 out of 10. Its ROE of -41% and ROA of -32.33% are underperforming 55% of other companies in the Global Biotechnology industry. Financial strength has a rating of 8 out of 10. The cash-debt ratio of 3.73 is below the industry median of 37.83.
The company’s largest shareholder among the gurus is Dodge & Cox with 10.91% of outstanding shares, followed by the Vanguard Health Care Fund with 9.92%, John Griffin (Trades, Portfolio) with 1.84%, Pioneer Investments with 0.1% and Simons with 0.06%.
Disclosure: I do not own any shares of any stocks mentioned in this article.
